FDA to Review Moderna's mRNA Flu Shot

- The initial refusal by the FDA's Center for Biologics Evaluation and Research (CBER), led by Dr. Vinay Prasad, stemmed from the clinical trial's design. The agency contended that the study did not use the "best-available standard of care" as a comparison for participants aged 65 and older, who are typically recommended a high-dose vaccine. - As a compromise, Moderna has sought a dual regulatory pathway: full approval for adults aged 50 to 64 and accelerated approval for those 65 and older. This agreement includes a commitment from Moderna to conduct an additional post-marketing study for the senior population. - The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026, for its decision on the vaccine, named mRNA-1010. If approved, the shot could be available for the 2026-2027 flu season. - In a large Phase 3 clinical trial involving over 40,000 participants, Moderna's mRNA flu shot was found to be more effective than a standard-dose licensed flu vaccine in adults aged 50 and older. The most common side effects reported were mild, including injection site pain, fatigue, headache, and muscle aches. - The development of this vaccine involves a range of life science careers. Bioinformatics scientists design and manage computational pipelines to analyze vast amounts of genetic and trial data. Their work is crucial for identifying vaccine targets and understanding the virus's evolution. - On the clinical side, Clinical Research Associates (CRAs) are essential for managing the trials. They travel to study sites, ensure protocols are followed correctly, verify data accuracy, and act as a key communication link between the pharmaceutical company and the doctors conducting the research. - Beyond the U.S., Moderna has also submitted applications for the vaccine's approval in Europe, Canada, and Australia, with decisions also anticipated in 2026.